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Table SI – Effects of 1-6 and Pt-Et on DPPH free radicals 
COMPOUND 
Percentage inhibition at different concentrations (%)* IC50 values 
(µg/mL)  25 µg/mL 50 µg/mL 75 µg/mL 100 µg/mL 
1 39.15±0.19 47.15±1.56 58.89±0.88 69.27±1.97 56.25 
2 34.25±0.36 46.88±0.52 62.90±0.09 76.53±0.11 60.0 
3 45.76±0.53 53.09±0.24 72.83±0.21 92.10±0.36 40.0 
4 30.89±0.89 48.79±0.92 55.98±0.99 69.97±0.96 53.0 
5 35.19±2.14 49.67±0.97 61.19±2.97 71.19±2.59 50.5 
6 43.61±0.30 48.05±0.38 59.61±0.32 70.11±0.30 53.5 
Pt-Et
#
 34.51±1.19 52.19±1.95 62.15±1.67 72.56±1.98 95.0 
Ascorbic acid 48.83±1.15 61.65±1.63 83.47±0.37 95.02±0.31 27.0 
*Mean±SD values (n=3); 
#























Table SII – Effects of 1-3 and Pt-Et on Superoxide free radicals 
COMPOUND 
Percentage inhibition at different concentrations (%)* IC50 values 
(µg/mL)  25 µg/mL 50 µg/mL 75 µg/mL 100 µg/mL 
1 30.18±3.11 42.18±2.96 57.87±2.68 66.17±2.17 62.5 
2 39.54±0.22 41.75±0.76 49.38±0.28 52.30±0.12 80.0 
3 49.58±0.21 55.25±0.54 68.56±0.11 78.99±0.09 26.0 
4 34.84±0.87 66.75±0.42 75.18±0.97 80.17±0.66 37.25 
5 39.18±2.54 62.67±2.87 71.14±2.17 82.17±2.24 36.0 
6 28.14±0.39 52.11±0.31 64.52±0.25 75.80±0.25 48.0 
Pt-Et
#
 32.11±1.13 50.15±1.15 69.18±1.87 82.16±2.18 99.75 
Ascorbic acid 45.74±0.68 56.17±0.71 76.00±0.74 93.10±0.64 35.5 
*Mean±SD values (n=3); 
#










Table SIII – Cytotoxicity studies of 1-6 and Pt-Et on six different cancer cell lines and normal 
human cell line. 
Sample
 
Percentage growth inhibition at 30 µg/mL concentration 
MDA-
MB-231 




































































































































Table SIV – Percentage growth inhibition and IC50 values of 1 and Pt-Et against SW620 
Sample Percentage growth inhibition (%) against SW620 IC50 values 
(µg/mL) 5 µg/mL 10 µg/mL 20 µg/mL 30 µg/mL 
1 19.75±1.91 31.58±5.80 44.75±2.37 52.57±3.80 26.5 
Pt-Et** 29.75±1.77 42.57±2.49 59.22±1.77 72.23±3.58 61.0 
Doxorubicin* 19.75±4.61 31.58±6.85 44.75±2.84 52.57±7.97 5.40 
n=3; *2.5, 5.0, 7.5 and 10 µg/mL concentrations; **25, 50, 75 and 100 µg/mL concentrations 
 
 
Table SV – Percentage growth inhibition and IC50 values of 4, 5 and Pt-Et against HeLa 
Sample Percentage growth inhibition (%) against HeLa IC50 values 
(µg/mL) 5 µg/mL 10 µg/mL 20 µg/mL 30 µg/mL 
4 12.74±2.28 19.57±5.66 32.18±5.62 56.80±2.17 27.0 
5 11.69±0.27 23.17±0.75 36.91±1.38 57.46±1.11 26.5 
Pt-Et** 26.47±2.97 37.18±2.52 50.17±3.58 70.17±4.61 74.5 
Doxorubicin* 41.01±3.85 52.14±2.84 68.88±1.77 85.55±6.24 4.5 









Table SVI – Percentage growth inhibition and IC50 values of 4, 5 and Pt-Et against FADU 
Sample Percentage  growth inhibition (%) against FADU IC50 values 
(µg/mL) 5 µg/mL 10 µg/mL 20 µg/mL 30 µg/mL 
4 23.74±3.77 38.17±3.25 50.17±4.89 60.80±2.45 20.0 
5 19.78±2.76 32.59±6.42 41.68±5.00 56.75±1.67 25.5 
Pt-Et** 28.79±3.37 40.18±3.75 59.47±5.48 74.01±2.15 62.5 
Doxorubicin* 42.79±1.78 56.25±2.83 75.98±4.59 65.40±0.60 3.8 
n=3; *2.5, 5.0, 7.5 and 10 µg/mL concentrations; **25, 50, 75 and 100 µg/mL concentrations 
 
 
Table SVII – Percentage growth inhibition and IC50 values of 4, 5 and Pt-Et against A549 
Sample Percentage  growth inhibition (%) against A549 IC50 values 
(µg/mL) 5 µg/mL 10 µg/mL 20 µg/mL 30 µg/mL 
4 14.15±5.64 33.18±4.76 45.89±1.67 61.20±1.78 22.5 
5 10.15±0.34 19.57±4.94 36.17±4.59 53.94±0.48 27.5 
Pt-Et** 28.47±2.20 40.17±0.42 57.18±0.29 74.01±2.15 64.9 
Doxorubicin* 26.12±4.54 42.63±5.48 56.10±4.03 65.40±0.60 6.3 










Figure S16 – SRB assay images of active samples at maximum tested concentration against 
SW620 
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